The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.
Georg Pfeiler
Honoraria - Amgen; GlaxoSmithKline; Novartis
Robert Königsberg
No relevant relationships to disclose
Lidija Filipcic
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose
Herbert Stoger
No relevant relationships to disclose
Christian F. Singer
No relevant relationships to disclose
Michael Knauer
Honoraria - AstraZeneca
Guenther G. Steger
Honoraria - AstraZeneca; Novartis
Michael Seifert
No relevant relationships to disclose
Peter Christian Dubsky
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis
Florian Fitzal
No relevant relationships to disclose
Marija Balic
No relevant relationships to disclose
Vesna Bjelic-Radisic
Honoraria - Amgen; AstraZeneca; Roche
Brigitte Mlineritsch
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Michael Gnant
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - Amgen; AstraZeneca; Novartis; Roche